Market Research Blog

According to the latest research by Future Market Insights, the skin antiseptic market is set to witness rapid growth during the forecast period (2021-2031). Demand for skin antiseptic witnessed rapid recovery in the short term, with an optimistic growth outlook in the long run. High demand for skin antiseptic expects to offer lucrative opportunities in near future, however, sales of skin antiseptic to treat the prevalence of infection will drive the market growth.

What are the Factors Likely to Drive the Skin Antiseptic Demand?

Due to the potential for contamination with pathogenic organisms and the increased likelihood of selecting potential and effective treatment for resistant organisms has surged demand for skin antiseptics that expects to drive the skin antiseptic market growth in coming years.

Ask for brochure of Market @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-13196

Sales of solution-based skin antiseptics are expected to offer lucrative opportunities for the European skin antiseptic market. Due to the growing prevalence of Surgical Site Infections (SSIs) and Healthcare-associated infections (HAIs) and the easy availability of various antiseptic solutions accounted for the highest revenue-generating category. Growing R&D and focus on efficacy improvement and growing applications of antiseptic solutions are expected to propel the segment further in the pre-operation and pre-injection procedures.

In addition based on the surgeries applications, the adoption of skin antiseptics is growing in the healthcare sector. Especially to reduce the risk of infection.

Chlorhexidine Gluconate Ingredient is Likely to Influence the Skin Antiseptic Sales

Chlorhexidine gluconate have been the dominating the global skin antiseptic market. According to a study published in Massachusetts Medical Society, concluded that chlorhexidine–alcohol has superior clinical efficacy and is more effective than povidine iodine-containing solutions in reducing the bacterial concentration in the operative field for vaginal hysterectomy.

US and Canada Skin Antiseptic Market Outlook

US is one of the largest markets for skin antiseptic globally. The US skin antiseptic market is set to tread on the historic pattern of bust and boom during the assessment period 2021-2031.

Demand for skin antiseptic in US and Canada will be led by negatively affecting the market growth by the increase with the rate of surgeries being performed. Pre-operative skin assessment is the initial step planned by the surgeon before the surgeries. Injection by application segment expects to project a steady growth in coming years. According to Consumer Healthcare Products estimation in US the OTC sales would reached between 36 and 37 billion U.S. dollars by 2020.

Europe Demand Outlook for Skin Antiseptic

Many countries in EU have severely been impacted by the COVID-19 crisis, which has led to a drop in economic activities. However, as is the case in US and Canada, pharmaceutical spending in EU continues to drive skin antiseptic demand.

In Europe, uncertainties in the wake of Brexit persist, especially concerning potential supply-chain disruptions, depending on how well the second phase of exit negotiations turns out. The UK pharmaceutical sector receives about 70% of imports from Europe. According to OECD data, around four out of every five euros are spent on retail pharmaceuticals goes on prescription medicines, while the rest on OTC medicines. The share of OTC medicines is particularly high in European countries such as Poland, accounting for half of the pharmaceutical spending, and stands for around 30% or more in Spain (36%), Cyprus (30%) and Latvia (31%) in 2018.

Who are the Key Manufacturers and Suppliers of Skin Antiseptic?

Some of the leading manufacturers and suppliers of skin antiseptic market include

• 3M Company
• BD
• Johnson & Johnson Services, Inc.
• Reckitt Benckiser
• B. Braun Melsungen AG
• Purdue Pharma L.P.
• EcoLab
• Schülke & Mayr GmbH
• PSK Pharma Pvt. Ltd.
• Kimberly-Clark
• Sirmaxo Chemicals Pvt. Ltd.
• Avrio Health L.P.
• Others

Growth strategies adopted by the leading pharmaceutical companies have influenced the market. The growing contribution by the key players as well as the governments to educate and spread awareness of antiseptic skin products are likely to boost the growth of the antiseptic skin industry substantially.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Skin Antiseptic Market Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

NOTE – All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-13196

Key Segments of Skin Antiseptic Market

By Ingredient Type:

• Alcohol
  • Isopropyl alcohol 70%
  • Ethyl alcohol 70%
• Chlorhexidine and other diguanide
  • Chlorhexidine acetate
  • Chlorhexidine gluconate
• Quaternary ammonium compound
  • Benzalkonium chloride
  • Cetrimide
  • Methylbenzethonium chloride
  • Benzethonium chloride
  • Cetalkonium chloride
  • Cetylpyridinium chloride
  • Others
• Halogenated phenol derivative
  • Chlorocresol
  • Chloroxylenol
  • Chlorophene
  • Other
• Antibacterial dye
  • Triphenylmethane
  • Proflavine hemisulphate
  • Brilliant green
  • Gentian violet
  • Crystal violet
• Peroxide and permanganate
  • Potassium permanganate solution
  • Hydrogen peroxide solution
  • Benzoyl peroxide
• Quinolone derivative
  • Hydroxyquinoline sulphate
  • Chlorquinaldol
  • Potassium hydroxyquinoline sulphate
  • Dequalinium chloride
  • Diiodohydroxyquinoline
• Miscellaneous
  • Burow’s solution (aqueous solution of aluminium acetate)
  • Bleach baths

By Form:

• Solutions
• Cream
• Spray
• Soaps
• Swab Sticks
• Wipes

By Type:

• Oral
• Topical

By Application:

• Wounds
• Surgeries

By Distribution Channel:

• Supermarket/ Hypermarket
• Drug Stores
• Retail Pharmacies
• E-commerce

 

According to latest research by Future Market Insights, pain patches market will experience substantial growth during the forecast period 2021-2031. Demand for pain patches will elevate in the course of forecast period while experiencing a steady growth. Increased demand pain patches to encounter the pain resulted from various medical conditions represents lucrative growth for pain patches market.

What is Driving Demand for Pain Patches?

Pain patch is a medicated adhesive patch that is used to relieve the pain by placing it on the skin. Pain patch uses a transdermal route and therefore provides an advantage of controlled delivery of medication as compared to other routes of administration. This advantage may result in increasing the sales of pain patches during the forecast period.

Ask for brochure of Market @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-13194

Increasing number of accidents that result in severe injury is expected to drive the growth of pain patches market across the globe. According to the Association for Safe International Travel, in 2020, approximately 4.4. million individuals were severely injured to require medical attention in the U.S. Moreover, increasing number of sports related injuries will also lead to a rise in demand for pain patch market.

In addition, changes in lifestyle and emergence of more office related jobs that needs continuous sitting in one position for too long may result in back related ailments among others. This will also lead to significant growth in the pain patches market.

Increasing Prevalence of Arthritis Expected to Augment the Growth of Pain Patches Market

Increasing chronic and acute pain related diseases is expected to reflect a positive growth for pain patches market. One such disease is arthritis which results in severe joint pain. The increasing prevalence of arthritis mainly is expected to increase the demand for pain patches. According to CDC, in 2018, an estimated 22.7% of the U.S. population of adults had doctor diagnosed arthritis.

U.S. and Canada Pain Patches Market Outlook

U.S. and Canada are among the largest market for pain patches market making North America a dominant player. The adoption of transdermal pain patches has increased in North America for pain management of certain conditions, which includes cancer. Pain patches are quite effective as compared to pain killers as they deliver pain management drugs at a predetermined rate across the dermis and achieve a local or a systemic effect.

This indicates that high prevalence of cancer will lead to rise in demand for pain patches market. According to National Cancer Institute, in 2018 an estimated 16,353,421 people living with cancer of any site in the U.S.

Europe Demand Outlook for Pain Patches

Increasing usage of pain patches for pain management for non-cancer conditions is expected to drive the growth of the pain patches market in this regions. Additionally, the increasing research and development funding and increasing focus of the European governments on the healthcare system also represents steady growth for pain patches market.

Moreover, favourable reimbursement policies in many European countries will also boost further growth of the pain patches market.

Who are the Key Manufacturers and Suppliers of Pain Patches?

Some of the leading manufacturers operating in the pain patches market include

• Viatris, Inc.
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Hisamitsu Pharmaceutical Co., Inc.
• GlaxoSmithKline Plc.
• Novartis AG
• Nichiban Co., Ltd.
• Teikoku Seiyaku Co, Ltd.
• Mentholatum Company.

Many leading manufacturers in the pain patches market are focusing on getting FDA approvals for their products. For instance, in July 2020, the FDA approved an 8% capsaicin pain patch for diabetic neuropathy. Manufacturers in the market are also focused carrying out acquisitions that will broaden their product portfolio. In July 2019, GlaxoSmithKline acquired the Pfizer’s Consumer Health Business which includes OTC products for topical pain management.

The Report Covers Exhaustive Analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2016 – 2020
• Market Size & Forecast 2021 to 2031
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Market Drivers and Restraints

Regional Analysis Includes:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

NOTE – All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-13194

Key Segments of Pain Patches Market

By Product Type:

• Opioid Patches
  • Buprenorphine
  • Fentanyl
• Non-opioid Patches
  • Diclofenac patches
  • Lidocaine patches
  • Ketoprofen patches
  • Capsaicin patches
  • Methyl Salicylate Patches

By Therapeutic Application:

• Pain relief
• Cough Suppression
• Anesthesia
• Diarrhea Suppression
• Smoking Cessation

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

 

According to the latest research by Future Market Insights, the Hearing amplifiers market is set to witness steady growth during 2021-2031. The rising prevalence of hearing impairment disorder, coupled with the growing geriatric population prone to hearing loss is increasing the demand for hearing amplifiers.

What Is Driving The Demand For The Hearing Amplifiers Market?

To meet the end-users demand for advanced, safe and cost-effective alternative to hearing aids devices continues to drive demand for hearing amplifiers in the market. Similarly, the increasing cost of hearing aids is creating huge opportunities for hearing amplifiers manufacturer to develop an advanced, cost-effective solution to solve the unmet demand of consumers.

Request for Report brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-13191

Growing Geriatric Population Is Likely To Accelerate The Demand for Hearing Amplifiers.

The growing geriatric population is a significant driving factor for the growth of the hearing amplifiers’ market. The geriatric population are more prone to hearing loss when compared with children. As per the world health organization (WHO), currently, about 466 million people have hearing problems across the globe and the number is projected to reach 900 million by 2050.  Among these, only 34 million are children. This number indicates growing geriatric population creates huge opportunities in the hearing amplifiers market.

The U.S. and Canada Hearing Amplifiers Market Outlook

The U.S. is one of the largest markets for hearing amplifiers globally. The U.S. Hearing amplifiers market is set to tread on the historic pattern of bust and boom during the assessment period 2021-2031.

Favorable healthcare policies, coupled with high per capita healthcare spending, has created a conducive environment for the adoption of hearing amplifier devices in the U.S. presence of leading players in the region is also expected to boost the market growth. Most of the key players are focusing on strategic acquisitions to strengthen their product portfolio.

For instance, in 2021, Amplifon S.p.A. acquired PJC Hearing, the hearing care business of PJC Investments LLC, which is the second-largest Miracle-Ear franchisee in the United States, which covers the major market in hearing care worldwide.

Europe Demand Outlook for Hearing Amplifiers Market

The rising prevalence of deafness, increasing awareness and the introduction of technologically advanced products are expected to contribute to the market growth of hearing amplifiers in Europe. Furthermore, favorable reimbursement policies accepted by each region of Europe is driving the growth of the market. Anteunis (1999) estimated that up to 52 million Europeans (20% of adults) and 36% of the older population suffer from some level of hearing handicap. According to the British MRC Institute of Hearing Research study, around 900 million people across the globe will suffer from hearing loss by 2025. Among this population, more than 90 million patients may be from Europe.

Who are the Key Manufacturers and Suppliers of Hearing amplifiers?

Some of the leading manufacturers and suppliers of hearing amplifiers include

• iHEAR Medical, Inc.
• Soundhawk
• FocusEar
• Resound
• Shenzhen LA Lighting Company Limited
• Foshan Vohom Technology Co. Ltd.
• MDHearingAid
• Beurer
• Etymotic Research
• IntriCon Corporation
• Britzgo
• Austar Hearing Science and Technology (Xiamen) Co., Ltd.
• Sound World Solutions
• Huizhou Jinghao Electronics Co. Ltd.
• Otofonix
• Banglijian
• Amplifon
• Ziphearing
• Others

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Hearing Amplifiers Market Report Highlights:

• Detailed overview of the parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

NOTE – All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-13191

Key Segments of Hearing Amplifiers Market

By Product Type:

• On the ear
• In the ear
• In-the-canal
• Behind-the-ear (BTE)
• Mini BTE

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
  • US
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • The U.K.
  • Germany
  • France
  • Spain
  • Russia
  • Benelux
  • Rest of Latin America
• East Asia
  • China
  • Japan
  • South Korea
• South Asia
  • India
  • ASEAN
  • Rest of South Asia
• Oceania
  • Australia
  • New Zealand
• The Middle East and Africa
  • GCC Countries
  • North Africa
  • South Africa
  • Turkey
  • Rest of the Middle East

 

According to the latest research by Future Market Insights, the research antibodies market will experience substantial growth during the forecast period 2021-2031. Demand for research antibodies will elevate in the course of the forecast period while experiencing steady growth. Increased demand for research antibodies in diagnostic purpose and determination of serious medical conditions represents lucrative growth for the research antibodies market.

What is Driving Demand for Research Antibodies?

Research specific antibodies are something where protein is used externally to detect the unwanted molecule into the body. It is basically used to understand what is going wrong in a cell or body. It acts as a biomarker to detect life-threatening diseases.

Increasing prevalence of chronic diseases and outbreak of infectious disease is expected to drive the growth of research antibodies market across the globe. According to World Health Organization, in 2020, approximately 1.5. Mn individuals were severely affected by an infectious disease like the coronavirus who require medical attention. Moreover, an increasing number of chronic disease patient like cancer, immunological disorders, etc. will also lead to a rise in demand for the research antibodies market.

Request for Report brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-13189

In addition, tremendous research in the field of chronic disease and its diagnosis mitigation and treatment. This will also lead to significant growth in the research antibodies market.

Increasing Prevalence of Chronic Disease may Grow Research Antibodies Market

Increasing prevalence of the chronic disease is expected to reflect positive growth for the Research Antibodies market. One such disease is cancer which results in severe life threatening condition. The increasing prevalence of cancer mainly is expected to increase the demand for Research Antibodies. According to National Cancer Institute, in 2018 an estimated 16,353,421 people living with cancer of any site in the U.S.

U.S. and Canada Research Antibodies Market Outlook

U.S. and Canada are among the largest market for research antibodies market making North America dominant. The U.S is growing due to high investments for the development of structure-based drug designs model, growing research in the fields of primary and secondary antibodies, and the focus of stakeholders on research projects involving proteins associated antibodies, research on biomolecules, and genes are the key driving factors of the market in U.S and Canada.

Europe Demand Outlook for Research Antibodies

Increasing usage of research antibodies for diagnostic and also in research work and clinical trials is expected to drive the growth of the research antibodies market in these regions. Additionally, the increasing research and development funding and increasing focus of the European governments on the healthcare system also represents steady growth for the research antibodies market.

Moreover, favourable reimbursement policies in many European countries will also boost further growth of the research antibodies market.

Who are the Key Manufacturers and Suppliers of Research Antibodies?

Some of the leading manufacturers operating in the research antibodies market include

• Thermo Fisher Scientific
• Merck Group
• Abcam plc
• Becton
• Dickinson and Company
• Bio-Rad Laboratories
• Cell Signaling Technology
• F. Hoffmann-La Roche
• Danaher Corporation
• Agilent Technologies
• PerkinElmer
• Lonza
• GenScript
• BioLegend
• Yashraj biotechnology Ltd.

Many leading manufacturers in the research antibodies market are focusing on getting FDA approvals for their products. For instance, In 2020, Thermo Fisher Scientific collaborated with Wuxi and Mayo Clinic To secure FDA authorization for testing COVID-19 with ELISA for detecting both IgM and IgG antibodies. In 2020, Merck partnered with Elypta to provide contract manufacturing services for Elypta’s clinical diagnostic liquid biopsy kits.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2016 – 2020
• Market Size & Forecast 2021 to 2031
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Market Drivers and Restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

NOTE – All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-13189

Key Segments of Research Antibodies Market

By Product Type:

• Primary Antibodies
  • Cancer research
  • Stem cell research
  • Neurobiology research
  • Epigenetics research
  • Infectious disease research
  • Apoptosis research
• Secondary Antibodies
  • Western Blotting
  • Flow Cytometry
  • ELISA
  • Immunohistochemistry
  • Immunofluorescence
  • Immunoprecipitation
  • Others
• Immune Checkpoint Antibodies

By Antibodies Form:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Others

By Source:

• Mice
• Rabbit
• Others

By Application:

• Drug Discovery & Development
• Basic Research
• Toxicity Screening
• Biopharmaceutical Production
• Drug Screening
• Tissue Engineering
• Forensic Testing

By End Users:

• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Forensic Science Laboratories
• Diagnostic Centers
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

 

Increasing demand for electrical stimulation to treat urinary incontinence is expected to boost the global pelvic floor stimulator market. According to a report by Future Market Insights (FMI), the global pelvic floor stimulator market was valued at US$ 110.4 Mn in 2020 and is predicted to expand at a CAGR of over 8.8% during the forecast period (2021–2031).

Weakening of pelvic floor muscles, urinary tract infections, menopause, constipation, obesity, and alcoholism are the main causes of urinary incontinence. The rising prevalence of these conditions, added to the growing elderly population, are major drivers for the global pelvic floor stimulators market.

Similarly, a high level of portability and lower costs of mobile devices in contrast to fixed devices or surgical treatments, and progressive therapeutic results and easy access to patients through over-the-counter (OTC) medical channels are expected to drive demand.\

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13187

Initiatives undertaken by government and non-governmental organizations to create awareness are increasing the demand for pelvic floor stimulators. For instance, the Australian government has started a program “National Continence Management Program.”

The government of Australia also started “The continence aids payment scheme (CAPS).” COVID-19 kicked the pelvic floor stimulators demand into high gear—and this extended to consumers increasing their adoption using online sales channels. However, lack of labor, halt on transportation, and disruptions in the supply chain, has affected device availability and growth prospects for the near future.

Manufacturers are focusing on research and development activities to develop unique and technologically advanced devices with rechargeable functionality. In March 2019 InControl Medical received FDA approval for a new Attain designed for at-home use to women in the U.S. suffering from stress, urge, mixed urinary incontinence or bowel incontinence.

Key Takeaways from Pelvic Floor Stimulator Market Study

• Electrical stimulators will reflect a revenue share of more than 66% with a CAGR of 9.1% owing to the high demand for treatment research for urinary incontinence.
• Urinary Incontinence holds a share of over 75% in 2021, due to the growing geriatric population which is prone to urinary incontinence.
• The U.K and Germany are leading markets in Europe, cumulatively accounting for over 45% of the regional value share, owing to consumer reliance on technology for health information.
• Driven by a matured healthcare and research sector, the U.S., will account for more than 78% of the North America market by 2031.
• China is a high potential market reflecting a 9.9% CAGR, driven by a rapidly growing consumer demographic of geriatrics.

 “Increasing prevalence of pelvic floor disorders and subsequently rising increasing awareness about the benefits electrical stimulation in the treatment of urinary incontinence are driving the adoption pelvic floor stimulators on a global scale through 2031,” says the FMI Analyst.   

Key Participant Insights

Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to expand their research and development capabilities, while increasing their sales by strengthening product portfolios in the pelvic floor stimulator market.

In August 2020, Medtronic expanded leadership to launch InterStim Micro Neurostimulator and InterStim SureScan MRI Leads, for treating bladder and bowel control conditions.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-13187

Want More Insights?

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels that provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global pelvic floor stimulator market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the pelvic floor stimulator market on basis of product type [Electrical stimulators and Magnetic Stimulators], application (Urinary Incontinence, Sexual Dysfunction and Neurodegenerative Diseases). Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.

 

Future Market Insights (FMI), in its latest publication, outlines the future trajectory of the global nucleic acid isolation and purification market through 2029. According to the report, worldwide sales of nucleic acid isolation and purification kits were valued at ~US$ 830 million in 2018, and are estimated to register a Y-o-Y growth of ~4% in 2019. As the consistency and reliability of molecular diagnostic results relies heavily on the quality of genetic material i.e. DNA and RNA, manufacturers are focusing on offering high-quality products, ensuring improved yield and purity.

With growing need to understand and characterize microbial diversity, including that associated with human body, governments as well as private companies are increasingly investing in life science projects, thereby creating a greater demand for nucleic acid isolation and purification. While the high cost challenge persists, shortage of skilled professionals in healthcare and biopharma industries remain the longstanding challenges.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-10035

Future market Insights’ study reveals that the nucleic acid isolation and purification market is likely to expand at a CAGR of ~5% during the period 2019-2029. One of the key influencing factors is manufacturers’ focus to direct their investments towards advanced technologies such as magnetic-bead or bead-beating technology, to align with end users’ demand for an effective system for extraction of high-quality starting material and efficient inhibitor removal. The unique challenges for extracting and purifying nucleic acid from different organisms and tissue types, have also brought more focus on customized systems and solutions.

Advances in Microbiome Research to Dictate Manufacturers’ Growth Strategies

In comparison with RNA isolation kits, manufacturers continue to increase innovations and production of DNA isolation kits, as the category is expected to account for larger share in the market during the forecast period. As per the study, lucrative opportunities are identified in increasing application scope of DNA isolation and purification kits in various academic research institutes, contract research organizations, and biotechnologies companies to not only successfully extract the DNA but also to minimize the presence of contaminants and prevent nucleic acid degradation during preparation. As genomic and microbiome research advances, manufacturers are working on automating the nucleic acid isolation and purifications kits to recover DNA and RNA from the toughest samples used in microbiome work such as soil and stool samples.

Growth prospects of the nucleic acid isolation and purification market, as the study opines, are relatively high in developed countries of North America and Europe. Hefty investments in R&D on molecular biology and precision medicines over gradual increase in the prevalence of cancer, genetic disorders, and complex diseases are likely to influence the manufacturers to enhance their production capabilities.

Tapping into opportunities in China and Japan for acquiring local players and increasing manufacturing facilities will provide the added advantage to gain a new customer base. As innovations zoom in, a number of market players are working on offering products that are free of toxic organic solvents and enable cost-effective method to extract and purify PCR-ready DNA or RT-PCR-ready RNA from numerous samples.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-10035

The report also offers an incisive outlook on the competitive landscape of nucleic acid isolation and purification market. As per the study, extensive M&A activities and new launches remain the key focus areas of the market players. In addition, they are emphasizing on strengthening outsourcing and solutions through strategic collaborations.

 

A new study of Future Market Insights (FMI) estimates the global spending on clinical trials in 2019 at ~US$ 90 Bn, recording a ~4% Y-o-Y over 2018. The healthcare sector is closing in on a new era of clinical trials, which are more engaged with patients, streamlined and connected. With development costs reaching record highs and patents approaching cliffs, companies are strengthening their R&D efforts to keep pace with change. Medical device and pharma giants are already eyeing better approaches for clinical trials, implementing a combination of their current systems and better technologies to ebb challenges in critical areas – orphan drugs and rare diseases.

According to the study, the clinical trials landscape is witnessing a paradigm shift toward patient centricity, in a bid to incorporate perspective of patients during the clinical trial design. Clinical trial sponsors have aligned their methods with the voice of patients, by launching communication channels during the study’s execution. Key enterprises are adopting unconventional approaches by implementing site-centric method, using operational support systems and technology for bringing studies to the trial-naïve physicians.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-384

Industry Sponsors Account for Majority Clinical Trial Spending

The most remarkable advances in medicine are realized from sponsorships of companies for clinical trials, in the anticipation of turning a profit. A notable percentage of clinical trials being conducted to support approval of vaccines, devices, or drugs, and track their safety, have been industry-sponsored in recent years.

The study estimates industry-sponsored clinical trials to account for ~60% of overall spending in 2019, and in the foreseeable future. Recent studies state that industry-sponsored trials yield positive results compared to academic-run trials, which also account for a significant share of clinical trial spending.

According to FMI, sponsors, such as academic institutes, research institutes and medical centers, are estimated to account for ~30% clinical trial spending in 2019. As the imperativeness of evidence-based therapies continue to be progressively emphasized, most of the randomized clinical trials are driven by the ability of developing profitable new therapies. Guidelines recommended by regulatory bodies for clinical trial enrichment, and risk-based monitoring are likely to lay the groundwork for more targeted approach toward cost-intensive clinical trials.

The study opines that North America and Europe will continue to lead the clinical trials landscape, collectively accounting for ~80% of global spending. These regions present a standardized and favorable environment for the clinical trials landscape, in light of their economic vigor that enables them to benefit from most of the technology disruptions prior to other nations. Pharmaceutical and medical device giants in these two regions are adopting AI for disrupting every stage of the clinical trial, which range from linking studies to eligible patients, to data collection and adherence.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-384

According to the study, opportunities abound for conducting clinical trials in developing economies, such as in East Asia and South Asia, owing to the access to huge patient pool. Sponsors are likely to realize greater success in these regions as low government healthcare budgets represent cost-effective methods of providing patients with access to innovative therapies. Additionally, conducting clinical trials in these regions comes with other broader advantages, including pragmatic & efficient regulatory pathway, and tax incentives for conducting the trials.

The study offers a long-term forecast of the clinical trials landscape for the period between 2019 and 2029. The clinical trials landscape is projected to record a 4.5% CAGR through 2029.

 

According to a new study of Future Market Insights (FMI), the small bore connectors market is estimated to roughly equate the revenues worth US$ 500 Mn in 2019, growing at ~4% over 2018. The small bore connectors industry remains influenced by a slew of factors, which range from the development of new international standards for design and performance, to the compelling requirement for higher-grade quality products that offer continued performance in high-stake situations.

The study offers a holistic perspective of the small bore connectors market for the period, 2019 to 2029. The small bore connectors market is forecast to record ~4% CAGR through 2029.

Security and safety is paramount in small bore connectors, while the rapidly growing space of medical equipment necessitates the development of disposable products with high performance vis-à-vis affordability.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3730

The study finds that the medical device industry and the standards community have been taking actions for minimizing the risk of misconnections. The profound emphasis on the development of new standards has led new connector designs come to the fore that are application-specific, preventing connections with other devices. Additionally, new non-standardized products have also been introduced by key players in the small bore connectors market, to curtail risks apropos of wrong route errors during the administration of medicine via neuraxial and enteral/oral routes.

Adoption Remains High in Intravascular and Enteral Administration of Medicine

The application scope of the small bore connectors spans wide, ranging from intravascular and enteral, to limb cuff inflation and neuraxial anaesthesia. Use of small bore connectors remains largest in intravascular administration of medicine, accounting for ~25% sales. As ISO/FDIS 80369-7 is finalised, small bore connector manufacturers are now bestowed with specifications for hypodermic and intravenous applications. Enteral administration of medicine also accounts for significant share of the small bore connectors market, owing to its high demand in feeding patients that are unable to drink and eat.

Small bore connector manufacturers are transitioning to new standards for addressing errors in connections between non-enteral and enteral devices. Key players are also focusing on providing succor to their customers by performing testing as part of the product development, to confirm compliance with standard requirements and demonstrate the functional performance of their products.

According to the study, developed markets remain the goldilocks zone for the small bore connector manufacturer. North America and Europe are collectively expected to account for ~50% sales of small bore connectors in 2019, and the status quo is likely to prevail in the foreseeable future. Profitability of developed markets for small bore connector manufacturers is advocated by the end-user and government actions based on regulations and competitive pricing.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3730

As medical device industry continues on its hunt for successful formulas for selling in developing markets, small bore connector manufacturers are following the suit. Developing economies are fairly benign for the small bore connectors market, pushed by growing number of initiatives and awareness campaigns by public as well as private organisations, abreast technology penetration and new product developments. Leading stakeholders in the small bore connectors market are adopting a ‘developing market mindset,’ even as emphasising reasonable investment horizon for eliminating mid-way profitability trap.

 

Deflectable catheters are used for minimally invasive procedures such as coronary interventions and electrophysiology applications. Due to the upgradation of technology, the core tip can deflect at a certain angle. According to the latest research by FMI, the global deflectable catheters market is expected to account for more than US$ 2,400.0 Mn in terms of value by the end of 2029. The deflectable catheters market report also projects a significant growth potential in the market with a CAGR of ~ 4% during the forecast period.

Companies Eyeing Untapped Opportunities in Cost-sensitive Regional Markets

The current adoption pattern among healthcare professionals favour the use of reposable medical devices, a trend that is most certainly observed in developing countries, to complement the cost factor and availability. In contrast, most of the deflectable catheters used are one-time use products. Factors like blood, debris prevent using reposable deflectable catheters in operations as critical as electrophysiology.

Get | Download Sample Copy with Graphs & List of Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-5852

The usage of reposable deflectable catheters is significantly higher in developing economies with inadequate resources, where the cost of treatment can be significantly high, which is unfavourable for patients from poor backgrounds. The present cost structure with the use of reposable deflectable catheters makes it feasible for a sizeable population to opt for low-cost treatment options, which help boost the adoption rate, and thereby expand the consumer pool.

At present, there are only a few companies offering reposable deflectable catheters, and none of the major players are into developing reposable devices. As per the report, a comparatively smaller company, CathRx, has a similar reposable product, Khelix, which is considered to be the first ‘reposable’ diagnostic and therapeutic catheter for the treatment of cardiac arrhythmias.

Acquisitions & Collaborations Playing Decisive Role in Shaping Deflectable Catheters Market Structure

The affective adjustments and development observed in the parent market influences the deflectable catheters market. The recent trend of involving digital methods for diagnosing cardiac problems is also changing the treatment pattern. All these trends are more governed by the top market leaders in the cardiology market. With abundant resources and investment plans, they manipulate the industry in a way in which no other smaller or regional manufacturer is capable of keeping pace with them.

The trend of acquisition and forming a strategic partnership is positive delivering financial results. For example, Abbott’s acquisition of St. Jude Medical resulted in the consolidation of the 2nd and 4th largest cardiology market players. Moreover, the acquisition of specific treatment technologies has also been observed in the deflectable catheter market, and there has been an increase in the number of players expanding their product portfolio for the treatment of atrial fibrillation/atrial flutter.

Deflectable Catheters Market: Segmental Analysis

On the basis of product type, the deflectable catheters market has been segmented into uni-directional deflectable catheters, bi-directional deflectable catheters, and multi-directional deflectable catheters. Bi-directional deflectable catheters lead the market due to their high adoption rate and availability.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-5852

Based on application, the deflectable catheters market has been segmented into coronary interventions, electrophysiology, diagnostics imaging, and peripheral interventions. In terms of revenue, the electrophysiology segment is expected to have a major share in the deflectable catheters market due to an increase in the number of procedures being carried out by deflectable catheters.

On the basis of end user, the deflectable catheters market has been categorised into hospitals, office-based clinics, ambulatory surgical centres, and independent catheterisation labs. Independent catheterisation labs are expected to witness significant growth, which is driven by an increase in the number of the same.

Some of the key players in the deflectable catheters market include Medtronic Plc, Merit Medical Systems, JOHNSON & JOHNSON, Teleflex Incorporated, Boston Scientific Corporation, Biomerics LLC, OSYPKA AG, Abbott, Japan Lifeline Co., CathRx Ltd., and Biotronik SE & Co. KG.

 

The rising prevalence of urinary incontinence in pregnant women, stress urinary incontinence due to diabetes, gynaecology disorders, and urinary incontinence in postmenopausal women are some of the major factors propelling the growth of the female stress urinary incontinence treatment devices market. Several other risk factors that increase the risk of developing stress urinary incontinence in women include high body weight, type of childbirth, age, pelvic surgery, etc.

A few medical conditions such as enlarged prostate, muscle damage, excess urine formation, multiple sclerosis, Parkinson’s disease, spinal cord injury, and loss of storage capacity in the rectum are also expected to boost the incidence of stress urinary incontinence among women, which is fuelling the demand for female stress urinary incontinence treatment devices.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2533

The practice of using female stress urinary incontinence treatment devices has changed dramatically over the past decade. The number of procedures undertaken appears to be increasing, and the shift in relative numbers of different procedures has been remarkable. For instance, in England, the annual number of operations undertaken using female stress urinary incontinence treatment devices between 1997-1998 and 2005-2006 increased by 28%, despite a reduction of over 90% in the number of colposuspension and needle suspension procedures.

Healthy Revenue Growth Projected through 2029

According to latest research by FMI, the global female stress urinary incontinence treatment devices market is estimated to have accounted for ~ US$ 560 Mn in terms of value in 2018. The report on the female stress urinary incontinence treatment devices market further projects that the female stress urinary incontinence treatment devices market is likely to grow at a CAGR of ~ 6% during the period 2019-2029.

However, due to the presence of wide range of products in the female stress urinary incontinence treatment devices market, small players are gaining interest and are selling their products at a lower price. Increase in the penetration of private-label brands at much lower prices is expected to decrease the average overall price of female stress urinary incontinence treatment devices. This is likely to restrain the growth of the global female stress urinary incontinence treatment devices market, as it is likely to hamper the demand for expensive products.

Rapid changes have taken place in developing countries over the past few years. The improper implementation of regulatory guidelines and the lack of proper healthcare infrastructure in developing regions, such as the Middle East & Africa and Latin America, are among factors that are expected to restrain the growth of the female stress urinary incontinence treatment devices market.

50% Revenue Shares Accounted by North America

The female stress urinary incontinence treatment devices market has been analysed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa. North America, followed by Europe, is a prominent region in the global female stress urinary incontinence treatment devices market. North America accounted for a revenue share of about 50% in 2018 in the female stress urinary incontinence treatment devices market. Europe also accounted for a prominent revenue share, and is followed by East Asia in the female stress urinary incontinence treatment devices market.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-2533

The female stress urinary incontinence treatment devices market report tracks some of the key companies operating in female stress urinary incontinence treatment devices market, such as Boston Scientific Corporation, BD, Coloplast Corporation, Caldera Medical, and Ethicon US LLC (Johnson & Johnson Services, Inc.). Majority of the key regional players in the female stress urinary incontinence treatment devices market highly focused on expanding their product connectivity and reach with the help of domestic distributors of female stress urinary incontinence treatment devices. Moreover, the manufacturers of female stress urinary incontinence treatment devices are focused to strengthening their businesses in high-growth markets, such as India, Japan, and China, by expanding their distribution and sales channels.